FN1 and prostate cancer: Targeting of critical intra- and extracellular focal adhesion components in prostate cancer cells, specifically talin, ILK, integrin-α6 and fibronectin by lead agent DZ-50, lifts anoikis resistance by inhibiting downstream survival signaling by AKT and GSK3β (Fig. 6).